摘要
异基因造血干细胞移植(Allo-HSCT)是某些血液系统恶性疾病惟一有望治愈的手段,也是某些血液系统非恶性疾病的重要治疗手段。HLA相合同胞供者是Allo-HSCT首选的供者来源,但是只有部分患者可以找到相合的同胞供者。因此,寻找合适的非血缘供者就变得十分重要。近年来,随着移植技术方案的成熟和支持治疗的进步,移植现状已获得明显的改善,非血缘供者造血干细胞移植疗效已达到了与同胞供者移植接近的水平。
Summary：Allogeneic hematopoietic stem cell transplantation （Allo-HSCT） has been the only promising ap- proach for a curative treatment of certain hematological malignancies and also an important intervention for some of non-malignant diseases. Since matched sibling donors are the first candidates among all donor sources ,only a small percentage of patients may have matched sibling donors. For those who do not, search of matched unrelated donor remains extremely important. In recent years, along with mature of transplantation techniques and development of supportive treatment, the use of HSCT has been greatly improved and the outcomes of HSCT using HLA matched unrelated donors have been somewhat similar to those with matched related donors. Due to the increasing number of one-child family in China, allogeneic hematopoietic stem cell transplantation （Allo-HSCT） can gradually be a major solution of stem cell transplantation.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2011年第2期146-148,共3页
Chinese Journal of Practical Internal Medicine
